{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:01:37Z","timestamp":1791072097995,"version":"4.1.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"vor","delay-in-days":78,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Swedish Research Council, Swedish Cancer Society and Stockholm Cancer Society, and the Stockholm County Council and Karolinska Institutet"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The Stockholm III trial randomly assigned 840 patients to short-course radiotherapy of 5 \u00d7 5 Gy with surgery within 1 week (SRT), short-course radiotherapy of 5 \u00d7 5 Gy with surgery after 4\u20138 weeks (SRT-delay), or long-course radiotherapy of 25 \u00d7 2 Gy with surgery after 4\u20138 weeks (LRT-delay). This study details the long-term oncological outcomes and health-related quality of life (HRQoL).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with biopsy-proven resectable adenocarcinoma of the rectum were included. Primary outcome was time to local recurrence (LR), and secondary endpoints were distant metastases (DMs), overall survival (OS), recurrence-free survival (RFS), and HRQoL. Patients were analysed in a three-arm randomization and a short-course radiotherapy comparison.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>From 1998 to 2013, 357, 355, and 128 patients were randomized to the SRT, SRT-delay, and LRT-delay groups respectively. Median follow-up time was 5.7 (range 5.3\u20137.6) years. Comparing patients in the three-arm randomization, the incidence of LR was three of 129 patients, four of 128, and seven of 128, and DM 31 of 129 patients, 38 of 128, and 38 of 128 in the SRT, SRT-delay, and LRT-delay groups respectively. In the short-course radiotherapy comparison, the incidence of LR was 11 of 357 patients and 13 of 355, and DM 88 of 357 patients and 82 of 355 in the SRT and SRT-delay groups respectively. No comparisons showed statistically significant differences. Median OS was 8.1 (range 6.9\u201311.2), 10.3 (range 8.2\u201312.8), and 10.5 (range 7.0\u201311.3) years after SRT, SRT-delay, and LRT-delay respectively. Median OS was 8.1 (range 7.2\u201310.0) years after SRT and 10.2 (range 8.5\u201311.7) years after SRT-delay. There were no statistically significant differences in HRQoL.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>After a follow-up of 5 years, delaying surgery for 4\u20138 weeks after radiotherapy treatment with 5 \u00d7 5 Gy was oncologically safe. Long-term HRQoL was similar among the treatment arms.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>NTC00904813<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjsopen\/zrab137","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T20:09:54Z","timestamp":1638389394000},"source":"Crossref","is-referenced-by-count":20,"title":["Radiotherapy regimens for rectal cancer: long-term outcomes and health-related quality of life in the Stockholm III trial"],"prefix":"10.1093","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9975-968X","authenticated-orcid":false,"given":"Johan","family":"Erlandsson","sequence":"first","affiliation":[{"name":"Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0661-0139","authenticated-orcid":false,"given":"Stina","family":"Fuentes","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calin","family":"Radu","sequence":"additional","affiliation":[{"name":"Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Erik","family":"Fr\u00f6din","sequence":"additional","affiliation":[{"name":"Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemming","family":"Johansson","sequence":"additional","affiliation":[{"name":"Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Brandberg","sequence":"additional","affiliation":[{"name":"Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torbj\u00f6rn","family":"Holm","sequence":"additional","affiliation":[{"name":"Department of Clinical Science and Education, S\u00f6dersjukhuset, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Glimelius","sequence":"additional","affiliation":[{"name":"Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Martling","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,1,18]]},"reference":[{"key":"2022020211592303800_zrab137-B1","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1056\/NEJM199704033361402","article-title":"Improved survival with pre-operative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial","volume":"336","author":"Swedish Rectal Cancer Trial","year":"1997","journal-title":"N Engl J Med"},{"key":"2022020211592303800_zrab137-B2","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/1097-0142(20010815)92:4<896::AID-CNCR1398>3.0.CO;2-R","article-title":"The Stockholm II trial on pre-operative radiotherapy in rectal carcinoma: long-term follow-up of a population-based study","volume":"92","author":"Martling","year":"2001","journal-title":"Cancer"},{"key":"2022020211592303800_zrab137-B3","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1056\/NEJMoa010580","article-title":"Pre-operative radiotherapy combined with total mesorectal excision for resectable rectal cancer","volume":"345","author":"Kapiteijn","year":"2001","journal-title":"N Engl J Med"},{"key":"2022020211592303800_zrab137-B4","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0140-6736(09)60484-0","article-title":"Pre-operative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial","volume":"373","author":"Sebag-Montefiore","year":"2009","journal-title":"Lancet"},{"key":"2022020211592303800_zrab137-B5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.radonc.2003.12.006","article-title":"Sphincter preservation following pre-operative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy","volume":"72","author":"Bujko","year":"2004","journal-title":"Radiother Oncol"},{"key":"2022020211592303800_zrab137-B6","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/j.ejso.2014.09.011","article-title":"Differences in pre-operative treatment for rectal cancer between Norway, Sweden, Denmark, Belgium and the Netherlands","volume":"40","author":"van den Broek","year":"2014","journal-title":"Eur J Surg Oncol"},{"key":"2022020211592303800_zrab137-B7","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.radonc.2007.11.025","article-title":"Short-course pre-operative radiotherapy with delayed surgery in rectal cancer \u2013 a retrospective study","volume":"87","author":"Radu","year":"2008","journal-title":"Radiother Oncol"},{"key":"2022020211592303800_zrab137-B8","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.radonc.2009.04.007","article-title":"Short-course radiotherapy, with elective delay prior to surgery, in patients with unresectable rectal cancer who have poor performance status or significant co-morbidity","volume":"92","author":"Hatfield","year":"2009","journal-title":"Radiother Oncol"},{"key":"2022020211592303800_zrab137-B9","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/bjs.7796","article-title":"Pre-operative short-course radiotherapy with delayed surgery in primary rectal cancer","volume":"99","author":"Pettersson","year":"2012","journal-title":"Br J Surg"},{"key":"2022020211592303800_zrab137-B10","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/00000658-198811000-00011","article-title":"Pre-operative radiotherapy as adjuvant treatment in rectal cancer. Final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC)","volume":"208","author":"G\u00e9rard","year":"1988","journal-title":"Ann Surg"},{"key":"2022020211592303800_zrab137-B11","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa060829","article-title":"Chemotherapy with pre-operative radiotherapy in rectal cancer","volume":"355","author":"Bosset","year":"2006","journal-title":"N Engl J Med"},{"key":"2022020211592303800_zrab137-B12","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.radonc.2018.05.004","article-title":"Pre-operative radiotherapy or chemoradiotherapy in rectal cancer \u2013 is survival improved? An update of the \u201cNordic\u201d LARC study in non-resectable cancers","volume":"127","author":"Br\u00e6ndengen","year":"2018","journal-title":"Radiother Oncol"},{"key":"2022020211592303800_zrab137-B13","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S1470-2045(17)30086-4","article-title":"Optimal fractionation of pre-operative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial","volume":"18","author":"Erlandsson","year":"2017","journal-title":"Lancet Oncol"},{"key":"2022020211592303800_zrab137-B14","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1097\/SLA.0000000000001987","article-title":"Acute adverse events and postoperative complications in a randomized trial of pre-operative short-course radiotherapy versus long-course chemoradiotherapy for T3 adenocarcinoma of the rectum: Trans-Tasman Radiation Oncology Group Trial (TROG 01.04)","volume":"265","author":"Ansari","year":"2017","journal-title":"Ann Surg"},{"key":"2022020211592303800_zrab137-B15","doi-asserted-by":"crossref","first-page":"e499","DOI":"10.1016\/j.clcc.2018.03.009","article-title":"Effect of neoadjuvant therapy and rectal surgery on health-related quality of life in patients with rectal cancer during the first 2 years after diagnosis","volume":"17","author":"Couwenberg","year":"2018","journal-title":"Clin Colorectal Cancer"},{"key":"2022020211592303800_zrab137-B16","doi-asserted-by":"crossref","first-page":"502","DOI":"10.3109\/0284186X.2015.1088171","article-title":"A comprehensive longitudinal overview of health-related quality of life and symptoms after treatment for rectal cancer in the TME trial","volume":"55","author":"Wiltink","year":"2016","journal-title":"Acta Oncol"},{"key":"2022020211592303800_zrab137-B17","doi-asserted-by":"crossref","first-page":"8697","DOI":"10.1200\/JCO.2005.02.9017","article-title":"Adverse effects of pre-operative radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial","volume":"23","author":"Birgisson","year":"2005","journal-title":"J Clin Oncol"},{"key":"2022020211592303800_zrab137-B18","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1080\/02841860701348670","article-title":"Late adverse effects of radiation therapy for rectal cancer \u2013 a systematic overview","volume":"46","author":"Birgisson","year":"2007","journal-title":"Acta Oncol"},{"key":"2022020211592303800_zrab137-B19","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.radonc.2019.03.016","article-title":"Tumour regression after radiotherapy for rectal cancer \u2013 results from the randomised Stockholm III trial","volume":"135","author":"Erlandsson","year":"2019","journal-title":"Radiother Oncol"},{"key":"2022020211592303800_zrab137-B20","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1080\/0284186X.2018.1529425","article-title":"Evaluation of the Swedish Colorectal Cancer Registry: an overview of completeness, timeliness, comparability and validity","volume":"57","author":"Moberger","year":"2018","journal-title":"Acta Oncol"},{"key":"2022020211592303800_zrab137-B21","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/BF00434800","article-title":"The European Organization for Research and Treatment of Cancer. Approach to quality of life assessment: guidelines for developing questionnaire modules. EORTC Study Group on Quality of Life","volume":"2","author":"Sprangers","year":"1993","journal-title":"Qual Life Res"},{"key":"2022020211592303800_zrab137-B22","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"2022020211592303800_zrab137-B23","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/028418600750013384","article-title":"Health-related quality of life measured by the EORTC QLQ-C30. Reference values from a large sample of the Swedish population","volume":"39","author":"Michelson","year":"2000","journal-title":"Acta Oncol"},{"key":"2022020211592303800_zrab137-B24","volume-title":"EORTC QLQ-C30 Scoring Manual","author":"Fayers","year":"2001","edition":"3rd edn)"},{"key":"2022020211592303800_zrab137-B25","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"key":"2022020211592303800_zrab137-B26","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1007\/s00384-015-2356-x","article-title":"Intensive surveillance following curative treatment of colorectal cancer allows effective treatment of recurrence even if limited to 4 years","volume":"30","author":"Adams","year":"2015","journal-title":"Int J Colorectal Dis"},{"key":"2022020211592303800_zrab137-B27","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ejso.2013.10.028","article-title":"Changing patterns of recurrent disease in colorectal cancer","volume":"40","author":"Grossmann","year":"2014","journal-title":"Eur J Surg Oncol"},{"key":"2022020211592303800_zrab137-B28","doi-asserted-by":"crossref","first-page":"O168","DOI":"10.1111\/codi.13060","article-title":"Time trends, improvements and national auditing of rectal cancer management over an 18-year period","volume":"17","author":"Kodeda","year":"2015","journal-title":"Colorectal Dis"},{"key":"2022020211592303800_zrab137-B29","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/02841860701802585","article-title":"The \u2018good\u2019, the \u2018bad\u2019, and the \u2018ugly\u2019 rectal cancers","volume":"47","author":"Blomqvist","year":"2008","journal-title":"Acta Oncol"},{"key":"2022020211592303800_zrab137-B30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/03009734.2016.1274806","article-title":"On a prolonged interval between rectal cancer (chemo)radiotherapy and surgery","volume":"122","author":"Glimelius","year":"2017","journal-title":"Ups J Med Sci"},{"key":"2022020211592303800_zrab137-B31","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1056\/NEJMoa040694","article-title":"Pre-operative versus postoperative chemoradiotherapy for rectal cancer","volume":"351","author":"Sauer","year":"2004","journal-title":"N Engl J Med"},{"key":"2022020211592303800_zrab137-B32","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1200\/JCO.2012.42.9597","article-title":"Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04","volume":"30","author":"Ngan","year":"2012","journal-title":"J Clin Oncol"},{"key":"2022020211592303800_zrab137-B33","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/bjs.5506","article-title":"Long-term results of a randomized trial comparing pre-operative short-course radiotherapy with pre-operative conventionally fractionated chemoradiation for rectal cancer","volume":"93","author":"Bujko","year":"2006","journal-title":"Br J Surg"},{"key":"2022020211592303800_zrab137-B34","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.radonc.2016.11.010","article-title":"Two countries \u2013 two treatment strategies for rectal cancer","volume":"121","author":"Glimelius","year":"2016","journal-title":"Radiother Oncol"},{"key":"2022020211592303800_zrab137-B35","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1200\/JCO.2011.39.7901","article-title":"Neoadjuvant treatment response as an early response indicator for patients with rectal cancer","volume":"30","author":"Park","year":"2012","journal-title":"J Clin Oncol"},{"key":"2022020211592303800_zrab137-B36","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1200\/JCO.2001.19.7.1976","article-title":"No downstaging after short-term pre-operative radiotherapy in rectal cancer patients","volume":"19","author":"Marijnen","year":"2001","journal-title":"J Clin Oncol"},{"key":"2022020211592303800_zrab137-B37","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0167-8140(96)01867-1","article-title":"Short-term pre-operative radiotherapy results in down-staging of rectal cancer: a study of 1316 patients","volume":"43","author":"Graf","year":"1997","journal-title":"Radiother Oncol"},{"key":"2022020211592303800_zrab137-B38","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/bjs.9112","article-title":"Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer","volume":"100","author":"Sloothaak","year":"2013","journal-title":"Br J Surg"},{"key":"2022020211592303800_zrab137-B39","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.ijrobp.2012.01.096","article-title":"Optimal timing for assessment of tumor response to neoadjuvant chemoradiation in patients with rectal cancer: do all patients benefit from waiting longer than 6 weeks?","volume":"84","author":"Perez","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2022020211592303800_zrab137-B40","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(14)71199-4","article-title":"Adjuvant chemotherapy after pre-operative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data","volume":"16","author":"Breugom","year":"2015","journal-title":"Lancet Oncol"},{"key":"2022020211592303800_zrab137-B41","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1080\/0284186X.2017.1344359","article-title":"What conclusions can be drawn from the Stockholm III rectal cancer trial in the era of watch and wait?","volume":"56","author":"Glimelius","year":"2017","journal-title":"Acta Oncol"},{"key":"2022020211592303800_zrab137-B42","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","article-title":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus pre-operative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial","volume":"22","author":"Bahadoer","year":"2021","journal-title":"Lancet Oncol"},{"key":"2022020211592303800_zrab137-B43","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.radonc.2020.03.039","article-title":"International expert consensus statement regarding radiotherapy treatment options for rectal cancer during the COVID 19 pandemic","volume":"148","author":"Marijnen","year":"2020","journal-title":"Radiother Oncol"}],"container-title":["BJS Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjsopen\/article-pdf\/5\/6\/zrab137\/42367063\/zrab137.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjsopen\/article-pdf\/5\/6\/zrab137\/42367063\/zrab137.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T12:00:10Z","timestamp":1643803210000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjsopen\/article\/doi\/10.1093\/bjsopen\/zrab137\/6510898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11,9]]}},"URL":"https:\/\/doi.org\/10.1093\/bjsopen\/zrab137","relation":{},"ISSN":["2474-9842"],"issn-type":[{"value":"2474-9842","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2021,11,1]]},"article-number":"zrab137"}}